Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · §2

Epithalon — pharmacology

Molecular targets, mechanism of action, pharmacokinetics and interactions as characterised in humans.

Document identifier
CEI-MN-039/2
Series
Compound monograph
Version
1.2
Published
26 May 2024
Last reviewed
26 Jan 2025
Next review
26 Jan 2027
Identifier
10.71829/cei.mono.39
Certainty
Very low
Cycle
2024 Q2

§2Pharmacology

§2.1Molecular targets

Table 2. Molecular targets recorded for Epithalon, with the character of the interaction and the potency where the Institute holds it.

TargetInteractionNote
Mechanism not establishedNo receptor identifiedReported effects on telomerase expression and on gene promoter methylation in cell culture; no receptor or defined mechanism established

§2.2Mechanism of action

Epithalon is supplied on the premise that it activates telomerase and thereby extends replicative lifespan, on the basis of cell-culture reports of telomerase induction in human somatic cells. The Institute notes that telomerase induction in culture is not an ageing endpoint, that the clinical literature is confined to a small number of Russian-language reports, and that no independent replication of the central telomerase finding has been identified.[1,2]

§2.3Pharmacokinetics

No human pharmacokinetic characterisation of Epithalon has been identified. In the absence of a half-life, a volume of distribution and a clearance estimate, no dosing interval used in practice can be related to any exposure that produced an effect in any study, and the Institute records this as a first-order gap rather than a detail.

§2.4Interactions

  • Not characterised

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS. Peptides and CCL11 and HMGB1 as differently expressed age-dependent proinflammatory biomarkers of ageing. Advances in Gerontology 2020;10(1):1–8. doi:10.1134/S2079057020010063
  2. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.